292 related articles for article (PubMed ID: 23623266)
1. Anti-IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis.
Otani IM; Anilkumar AA; Newbury RO; Bhagat M; Beppu LY; Dohil R; Broide DH; Aceves SS
J Allergy Clin Immunol; 2013 Jun; 131(6):1576-82. PubMed ID: 23623266
[TBL] [Abstract][Full Text] [Related]
2. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis.
Assa'ad AH; Gupta SK; Collins MH; Thomson M; Heath AT; Smith DA; Perschy TL; Jurgensen CH; Ortega HG; Aceves SS
Gastroenterology; 2011 Nov; 141(5):1593-604. PubMed ID: 21835135
[TBL] [Abstract][Full Text] [Related]
3. Transient PPI responsive esophageal eosinophilia may be a clinical sub-phenotype of pediatric eosinophilic esophagitis.
Dohil R; Newbury RO; Aceves S
Dig Dis Sci; 2012 May; 57(5):1413-9. PubMed ID: 22134787
[TBL] [Abstract][Full Text] [Related]
4. Expanding the paradigm of eosinophilic esophagitis: mast cells and IL-9.
Wang YH; Hogan SP; Fulkerson PC; Abonia JP; Rothenberg ME
J Allergy Clin Immunol; 2013 Jun; 131(6):1583-5. PubMed ID: 23726533
[No Abstract] [Full Text] [Related]
5. Increased numbers of eosinophils, rather than only etiology, predict histologic changes in patients with esophageal eosinophilia.
Sridhara S; Ravi K; Smyrk TC; Kita H; Kephart GM; Weiler CR; Katzka DA
Clin Gastroenterol Hepatol; 2012 Jul; 10(7):735-41. PubMed ID: 22289868
[TBL] [Abstract][Full Text] [Related]
6. Serum eosinophil cationic protein is superior to mast cell tryptase as marker for response to topical corticosteroid therapy in eosinophilic esophagitis.
Schlag C; Pfefferkorn S; Brockow K; Haller B; Slotta-Huspenia J; Schulz S; von Werder A; Ring J; Schmid RM; Bajbouj M
J Clin Gastroenterol; 2014 Aug; 48(7):600-6. PubMed ID: 24177377
[TBL] [Abstract][Full Text] [Related]
7. Mast Cell Infiltration Is Associated With Persistent Symptoms and Endoscopic Abnormalities Despite Resolution of Eosinophilia in Pediatric Eosinophilic Esophagitis.
Bolton SM; Kagalwalla AF; Arva NC; Wang MY; Amsden K; Melin-Aldana H; Dellon ES; Bryce PJ; Wershil BK; Wechsler JB
Am J Gastroenterol; 2020 Feb; 115(2):224-233. PubMed ID: 31913192
[TBL] [Abstract][Full Text] [Related]
8. Tryptase staining of mast cells may differentiate eosinophilic esophagitis from gastroesophageal reflux disease.
Dellon ES; Chen X; Miller CR; Fritchie KJ; Rubinas TC; Woosley JT; Shaheen NJ
Am J Gastroenterol; 2011 Feb; 106(2):264-71. PubMed ID: 20978486
[TBL] [Abstract][Full Text] [Related]
9. Esophageal mast cells may be associated with the perception of symptoms in patients with eosinophilic esophagitis.
Kanamori A; Tanaka F; Takashima S; Sawada A; Ominami M; Nadatani Y; Fukunaga S; Otani K; Hosomi S; Kamata N; Nagami Y; Taira K; Watanabe T; Fujiwara Y
Esophagus; 2023 Apr; 20(2):333-341. PubMed ID: 36342564
[TBL] [Abstract][Full Text] [Related]
10. Atopic and non-atopic eosinophilic oesophagitis are distinguished by immunoglobulin E-bearing intraepithelial mast cells.
Mulder DJ; Mak N; Hurlbut DJ; Justinich CJ
Histopathology; 2012 Nov; 61(5):810-22. PubMed ID: 22978418
[TBL] [Abstract][Full Text] [Related]
11. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis.
Stein ML; Collins MH; Villanueva JM; Kushner JP; Putnam PE; Buckmeier BK; Filipovich AH; Assa'ad AH; Rothenberg ME
J Allergy Clin Immunol; 2006 Dec; 118(6):1312-9. PubMed ID: 17157662
[TBL] [Abstract][Full Text] [Related]
12. Mast Cell and Eosinophil Counts in Gastric and Duodenal Biopsy Specimens From Patients With and Without Eosinophilic Gastroenteritis.
Reed CC; Genta RM; Youngblood BA; Wechsler JB; Dellon ES
Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2102-2111. PubMed ID: 32801015
[TBL] [Abstract][Full Text] [Related]
13. Elevated Tryptase in EoE Is an Independent Phenomenon Associated with Extra-Esophageal Symptoms.
Kutty GR; Downs-Kelly E; Crispin HT; Peterson KA
Dig Dis Sci; 2019 Jan; 64(1):152-157. PubMed ID: 30267171
[TBL] [Abstract][Full Text] [Related]
14. Machine learning-based identification and characterization of mast cells in eosinophilic esophagitis.
Zhang S; Caldwell JM; Rochman M; Collins MH; Rothenberg ME
J Allergy Clin Immunol; 2024 May; 153(5):1381-1391.e6. PubMed ID: 38395083
[TBL] [Abstract][Full Text] [Related]
15. Molecular basis and cellular mechanisms of eosinophilic esophagitis for the clinical practice.
Arias Á; Lucendo AJ
Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):99-117. PubMed ID: 30791784
[TBL] [Abstract][Full Text] [Related]
16. Long-term assessment of esophageal remodeling in patients with pediatric eosinophilic esophagitis treated with topical corticosteroids.
Rajan J; Newbury RO; Anilkumar A; Dohil R; Broide DH; Aceves SS
J Allergy Clin Immunol; 2016 Jan; 137(1):147-156.e8. PubMed ID: 26233926
[TBL] [Abstract][Full Text] [Related]
17. Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis.
Rothenberg ME; Wen T; Greenberg A; Alpan O; Enav B; Hirano I; Nadeau K; Kaiser S; Peters T; Perez A; Jones I; Arm JP; Strieter RM; Sabo R; Gunawardena KA
J Allergy Clin Immunol; 2015 Feb; 135(2):500-7. PubMed ID: 25226850
[TBL] [Abstract][Full Text] [Related]
18. Biological Therapies for Eosinophilic Esophagitis: Where Do We Stand?
Ko E; Chehade M
Clin Rev Allergy Immunol; 2018 Oct; 55(2):205-216. PubMed ID: 29372536
[TBL] [Abstract][Full Text] [Related]
19. Expression of CD25, mast cell markers and T-cell markers in eosinophilic esophagitis.
Htoo A; Qualia CM; George R; Arker SH; Subasi NB; Lee H; Chung L; Chen A
Ann Diagn Pathol; 2024 Jun; 70():152287. PubMed ID: 38479198
[TBL] [Abstract][Full Text] [Related]
20. Vasoactive Intestinal Peptide Receptor, CRTH2, Antagonist Treatment Improves Eosinophil and Mast Cell-Mediated Esophageal Remodeling and Motility Dysfunction in Eosinophilic Esophagitis.
Yadavalli CS; Upparahalli Venkateshaiah S; Verma AK; Kathera C; Duncan PS; Vaezi M; Paul RJ; Mishra A
Cells; 2024 Feb; 13(4):. PubMed ID: 38391908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
